Browse ITPR3

Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane; Multi-pass membrane protein.
Domain PF08709 Inositol 1
PF00520 Ion transport protein
PF02815 MIR domain
PF08454 RyR and IP3R Homology associated
PF01365 RIH domain
Function

Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium.

> Gene Ontology
 
Biological Process GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0007611 learning or memory
GO:0007613 memory
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0019932 second-messenger-mediated signaling
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030168 platelet activation
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0035637 multicellular organismal signaling
GO:0042886 amide transport
GO:0044057 regulation of system process
GO:0044708 single-organism behavior
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048016 inositol phosphate-mediated signaling
GO:0048167 regulation of synaptic plasticity
GO:0050708 regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0050890 cognition
GO:0050909 sensory perception of taste
GO:0050913 sensory perception of bitter taste
GO:0050916 sensory perception of sweet taste
GO:0050917 sensory perception of umami taste
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051291 protein heterooligomerization
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051592 response to calcium ion
GO:0055074 calcium ion homeostasis
GO:0060047 heart contraction
GO:0060291 long-term synaptic potentiation
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0061337 cardiac conduction
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0097553 calcium ion transmembrane import into cytosol
GO:1902656 calcium ion import into cytosol
GO:1903522 regulation of blood circulation
GO:1903779 regulation of cardiac conduction
GO:2000021 regulation of ion homeostasis
Molecular Function GO:0000822 inositol hexakisphosphate binding
GO:0005216 ion channel activity
GO:0005217 intracellular ligand-gated ion channel activity
GO:0005220 inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0005543 phospholipid binding
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0015278 calcium-release channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022834 ligand-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0035091 phosphatidylinositol binding
GO:0043178 alcohol binding
GO:0043533 inositol 1,3,4,5 tetrakisphosphate binding
GO:0046873 metal ion transmembrane transporter activity
GO:0070679 inositol 1,4,5 trisphosphate binding
GO:0072509 divalent inorganic cation transmembrane transporter activity
GO:0099604 ligand-gated calcium channel activity
Cellular Component GO:0005635 nuclear envelope
GO:0005640 nuclear outer membrane
GO:0005903 brush border
GO:0016528 sarcoplasm
GO:0016529 sarcoplasmic reticulum
GO:0019867 outer membrane
GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0031094 platelet dense tubular network
GO:0031095 platelet dense tubular network membrane
GO:0031965 nuclear membrane
GO:0031968 organelle outer membrane
GO:0043025 neuronal cell body
GO:0043209 myelin sheath
GO:0043235 receptor complex
GO:0044297 cell body
GO:0045177 apical part of cell
GO:0098862 cluster of actin-based cell projections
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04070 Phosphatidylinositol signaling system
hsa04114 Oocyte meiosis
hsa04210 Apoptosis
hsa04270 Vascular smooth muscle contraction
hsa04540 Gap junction
hsa04611 Platelet activation
hsa04621 NOD-like receptor signaling pathway
hsa04713 Circadian entrainment
hsa04720 Long-term potentiation
hsa04723 Retrograde endocannabinoid signaling
hsa04724 Glutamatergic synapse
hsa04725 Cholinergic synapse
hsa04726 Serotonergic synapse
hsa04728 Dopaminergic synapse
hsa04730 Long-term depression
hsa04742 Taste transduction
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04911 Insulin secretion
hsa04912 GnRH signaling pathway
hsa04915 Estrogen signaling pathway
hsa04918 Thyroid hormone synthesis
hsa04921 Oxytocin signaling pathway
hsa04922 Glucagon signaling pathway
hsa04970 Salivary secretion
hsa04971 Gastric acid secretion
hsa04972 Pancreatic secretion
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607763: CLEC7A (Dectin-1) induces NFAT activation
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-4086398: Ca2+ pathway
R-HSA-5576891: Cardiac conduction
R-HSA-1489509: DAG and IP3 signaling
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-186763: Downstream signal transduction
R-HSA-212718: EGFR interacts with phospholipase C-gamma
R-HSA-114508: Effects of PIP2 hydrolysis
R-HSA-139853: Elevation of cytosolic Ca2+ levels
R-HSA-2871809: FCERI mediated Ca+2 mobilization
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-416476: G alpha (q) signalling events
R-HSA-112040: G-protein mediated events
R-HSA-388396: GPCR downstream signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-381676: Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-163685: Integration of energy metabolism
R-HSA-5578775: Ion homeostasis
R-HSA-1430728: Metabolism
R-HSA-397014: Muscle contraction
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-111885: Opioid Signalling
R-HSA-112043: PLC beta mediated events
R-HSA-167021: PLC-gamma1 signalling
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-418360: Platelet calcium homeostasis
R-HSA-418346: Platelet homeostasis
R-HSA-422356: Regulation of insulin secretion
R-HSA-2029485: Role of phospholipids in phagocytosis
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-186797: Signaling by PDGF
R-HSA-194138: Signaling by VEGF
R-HSA-195721: Signaling by Wnt
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITPR3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITPR3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.58 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITPR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2460.612
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1150.953
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3680.729
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.920.0207
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0020.714
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8190.819
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3020.568
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7370.682
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1560.937
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0550.965
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9260.572
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0460.626
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITPR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITPR3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITPR3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITPR3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITPR3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITPR3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITPR3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITPR3
Nameinositol 1,4,5-trisphosphate receptor, type 3
Aliases IP3R3; inositol 1,4,5-triphosphate receptor, type 3; insP3R3; type 3 InsP3 receptor; Type 3 inositol 1,4,5-t ......
Chromosomal Location6p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITPR3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ITPR3.
ID Name Drug Type Targets #Targets
DB00201CaffeineSmall MoleculeADORA1, ADORA2A, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, ......33